Biomarin Pharmaceutical (BMRN) Return on Capital Employed (2010 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Return on Capital Employed came in at 4.32% in Q1 2026, down 530.0% YoY from 1.0% in Q1 2025, and down 27.81% on a QoQ basis from 5.98% in Q4 2025.
Biomarin Pharmaceutical (BMRN) Return on Capital Employed (2010 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 17 years of Return on Capital Employed data on file, last reported at 4.32% in Q1 2026.
- Quarterly Return on Capital Employed fell 530.0% year-over-year to 4.32% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.32% (down 530.0% YoY) and the FY2025 annual result came in at 6.27%, down 141.0% from the prior year.
- Return on Capital Employed retreated to 4.32% in Q1 2026, from 5.98% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 11.73% in Q2 2025 to a low of 0.54% in Q1 2022.
- A 5-year average of 4.58% and a median of 3.67% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed soared 721 bps — and 2026, when it tumbled 530 bps.
- Tracing BMRN's Return on Capital Employed over 5 years: stood at 2.81% in 2022, then grew by 18 bps to 3.3% in 2023, then soared by 132 bps to 7.67% in 2024, then slipped by 22 bps to 5.98% in 2025, then decreased by 28 bps to 4.32% in 2026.
- The last three Return on Capital Employed figures came in at 4.32% (Q1 2026), 5.98% (Q4 2025), and 9.14% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 1.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76% |
| Mar 31, 2026 | 4.32% |
| Dec 31, 2025 | 5.98% |
| Sep 30, 2025 | 9.14% |
| Jun 30, 2025 | 11.73% |
| Mar 31, 2025 | 9.62% |
| Dec 31, 2024 | 7.67% |
| Sep 30, 2024 | 5.61% |
| Jun 30, 2024 | 4.52% |
| Mar 31, 2024 | 3.67% |
| Dec 31, 2023 | 3.30% |
| Sep 30, 2023 | 2.64% |
| Jun 30, 2023 | 1.91% |
| Mar 31, 2023 | 1.48% |
| Dec 31, 2022 | 2.81% |
| Sep 30, 2022 | 1.90% |
| Jun 30, 2022 | 1.02% |
| Mar 31, 2022 | 0.54% |
| Dec 31, 2021 | -1.51% |
| Sep 30, 2021 | -1.25% |